Gsa Capital Partners LLP Biotechnology

Gsa Capital Partners LLP

$1.32 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
INZY Inozyme Pharma, Inc.	$140M	$185,000 0.01% of portfolio	35,402	Q3 2024 Reduced 13.51%
ATHA Athira Pharma, Inc.	$26.9M	$177,000 0.01% of portfolio	397,111	Q3 2024 Added 909.84%
VERV Verve Therapeutics, Inc.	$322M	$175,000 0.01% of portfolio	36,102	Q3 2024 Reduced 82.27%
NUVB Nuvation Bio Inc.	$623M	$172,000 0.01% of portfolio	74,932	Q3 2024 New
ERAS Erasca, Inc.	$343M	$166,000 0.01% of portfolio	60,848	Q3 2024 Reduced 46.33%
VNDA Vanda Pharmaceuticals Inc.	$288M	$143,000 0.01% of portfolio	30,423	Q3 2024 New
TPST Tempest Therapeutics, Inc.	$10.2M	$133,000 0.01% of portfolio	94,912	Q3 2024 Reduced 6.07%
CABA Cabaletta Bio, Inc.	$115M	$127,000 0.01% of portfolio	26,976	Q3 2024 New
HLVX Hille Vax, Inc.	$64.5M	$126,000 0.01% of portfolio	71,463	Q3 2024 New
PBYI Puma Biotechnology, Inc.	$136M	$126,000 0.01% of portfolio	49,494	Q3 2024 Reduced 73.92%
CMPX Compass Therapeutics, Inc.	$161M	$121,000 0.01% of portfolio	65,922	Q2 2024 New
STTK Shattuck Labs, Inc.	$58.1M	$121,000 0.01% of portfolio	34,699	Q3 2024 New
RLAY Relay Therapeutics, Inc.	$673M	$109,000 0.01% of portfolio	15,407	Q3 2024 Reduced 84.34%
PMVP Pmv Pharmaceuticals, Inc.	$73M	$109,000 0.01% of portfolio	73,352	Q3 2024 Reduced 5.65%
RVNC Revance Therapeutics, Inc.	$212M	$108,000 0.01% of portfolio	20,819	Q3 2024 New
QSI Quantum Si Inc	$93.2M	$99,000 0.01% of portfolio	112,317	Q3 2024 Reduced 38.38%
MNKD Mannkind Corp	$1.81B	$97,000 0.01% of portfolio	15,342	Q3 2024 Reduced 96.74%
CRMD Cor Medix Inc.	$453M	$96,000 0.01% of portfolio	11,825	Q3 2024 Reduced 71.92%
ADAP Adaptimmune Therapeutics PLC	$96.4M	$95,000 0.01% of portfolio	99,662	Q3 2024 New
ALXO Alx Oncology Holdings Inc	$54.2M	$88,000 0.01% of portfolio	48,204	Q3 2024 New
CCCC C4 Therapeutics, Inc.	$231M	$88,000 0.01% of portfolio	15,446	Q3 2024 Reduced 33.62%
LCTX Lineage Cell Therapeutics, Inc.	$149M	$84,000 0.01% of portfolio	93,032	Q3 2024 New
XERS Xeris Biopharma Holdings, Inc.	$415M	$78,000 0.01% of portfolio	27,350	Q3 2024 Reduced 95.48%
GOSS Gossamer Bio, Inc.	$72.3M	$67,000 0.01% of portfolio	67,546	Q3 2024 New
TSVT 2seventy Bio, Inc.	$148M	$64,000 0.0% of portfolio	13,479	Q3 2024 New
FULC Fulcrum Therapeutics, Inc.	$173M	$61,000 0.0% of portfolio	17,142	Q3 2024 Reduced 87.32%
ACET Adicet Bio, Inc.	$42M	$56,000 0.0% of portfolio	39,208	Q3 2024 Added 161.3%
IMUX Immunic, Inc.	$33M	$54,000 0.0% of portfolio	32,766	Q3 2024 Reduced 71.94%
AADI Aadi Bioscience, Inc.	$45.6M	$43,000 0.0% of portfolio	21,097	Q3 2024 Reduced 23.25%
GLYC Glycomimetics Inc	$20.4M	$14,000 0.0% of portfolio	83,725	Q3 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.